Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Evaluation of Image-based Artificial Intelligence Research and Development Tool for Precision Neoadjuvant Triple-Negative Breast Cancer Treatment

NCT05435352 is registered in ClinicalTrials.gov with Ourotech, Inc. as lead sponsor.

NCT NCT05435352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05435352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Evaluation of Image-based Artificial Intelligence Research and Development Tool for Precision Neoadjuvant Triple-Negative Breast Cancer Treatment
Lead sponsor
Ourotech, Inc.
Phase
Observational
Overall status
Terminated
Start date
June 6, 2022
Completion date
July 25, 2025
Enrollment
34 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer, triple negative breast neoplasms